



TSX-V: CST

Outstanding shares: 60,261,136

For Immediate Release

CO₂ Solution Scientific Advisory Board Member Dr. Roger Sheldon Honored for Lifetime Achievements in Green Chemistry and Biocatalysis

Quebec City, QC, Canada and Delft, The Netherlands, December 15th, 2010 – CO₂ Solution Inc. is pleased to congratulate Dr. Roger Sheldon on his recent receipt of two prestigious awards in the fields of Green Chemistry and Biocatalysis. Dr. Sheldon is a member of CO₂ Solution's Scientific Advisory Board and founder and Chief Executive Officer of CLEA Technologies B.V., a strategic collaborator of CO₂ Solution for carbon capture enzyme immobilization.

Dr. Sheldon was awarded the 2010 Green Chemistry Award from the Royal Society of Chemistry (RSC). The Green Chemistry Award is presented each year by the RSC, Europe's largest organization for the advancement of chemical sciences, for the design, development or implementation of novel chemical products or processes which have the potential to reduce or eliminate the use and generation of hazardous substances. Dr. Sheldon received the 2010 award in recognition of the role that he has played as one of the founding fathers of green chemistry and in particular for his work on the development of clean, catalytic technologies for waste minimization and elimination of toxic/hazardous materials in chemicals manufacture.

He was also recently bestowed the honor of receiving the International Congress on Biocatalysis (Biocat) Award for Lifetime Achievement. Since 2002, Biocat has been a leading conference series bringing together international research leaders for knowledge sharing in the rapidly growing fields of biocatalysis and industrial biotechnology. The Biocat Award for Lifetime Achievement honours individuals who have made outstanding contributions over their careers to the field of biocatalysis, and advancing biocatalytic research to enable greener and more efficient industrial processes. Dr. Sheldon received the 2010 award for his lifelong commitment to advancing biocatalysis and his exemplary achievements in both academia and private.

Glenn Kelly, President and CEO of CO₂ Solution stated, "We congratulate Dr. Sheldon on these significant accomplishments. As he is known as the 'father of green chemistry' amongst his peers, these awards honour his lifelong dedication to this important area of scientific and technical endeavour. We are very pleased that we can access this knowledge and dedication to the benefit of our green industrial process that harnesses nature's power for the capture of carbon".

About Dr. Roger Sheldon

In addition to being the founder and Chief Executive Officer of CLEA Technologies B.V., a leading developer of proprietary enzyme utilization and immobilization technologies, Dr. Sheldon is Professor Emeritus and previous Chair of Biocatalysis and Organic Chemistry at Delft University of Technology, in the Netherlands, a position he held from 1991 until 2008. Prior to this, Dr. Sheldon was Vice-President of Research & Development for DSM N.V., a leading multi-national life sciences and chemical company from 1980 until 1991. Dr. Sheldon is a respected authority on the use of biocatalysts for industrial processes and was the first Chairman of the Editorial Board that established the successful journal, Green Chemistry. He has published more than 400 technical papers, 50 patents and six books on the subject of catalysis. Dr. Sheldon is particularly known for his work in designing multi-step catalytic processes which imitate the metabolic pathways in living cells.

About the Agreement with CLEA Technologies

In June 2010, CO₂ Solution entered into a Custom Immobilization Agreement with CLEA Technologies B.V. ("CLEATECH") (www.cleatechnologies.com) for the application of CLEATECH's proprietary Cross Linked Enzyme Aggregates ("CLEA") technology for the carbonic anhydrase enzymes used by CO₂ Solution for carbon capture applications. CLEATECH is a leader in enzyme immobilization and the development of green (biocatalytic) processes for the chemical and allied industries. CLEATECH's proprietary technology for the immobilization of enzymes as CLEAs has broad scope and affords robust biocatalysts with improved stability and recyclability coupled with high productivities. This enables economically viable applications of enzymes in a variety of settings. As part of the Agreement, CO₂ Solution obtained exclusive global rights to CLEATECH's CLEA technology for the enzyme carbonic anhydrase.

About CO₂ Solution

Based in Quebec City, CO₂ Solution is an innovator in the field of enzyme enabled carbon capture and has been actively working to develop and commercialize the technology for power plants and other large stationary sources of carbon pollution. In the process, CO₂ Solution has built an extensive patent portfolio covering the use of carbonic anhydrase for the efficient post-combustion capture of carbon dioxide with low-energy aqueous solvents. Further information can be found at www.co2solution.com.

Forward Looking Statements

Certain statements in this news release may be forward-looking. These statements relate to future events or CO₂ Solution's future economic performance and reflect the current assumptions and expectations of management. Certain unknown factors may affect the events, economic performance and results of operation described herein. CO₂ Solution undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

-30-

Contacts:

CO₂ Solution: Helene Savoie, helene.savoie@co2solution.com, 418 842-3456.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.